LENZ Therapeutics holders elect Class II directors
LENZ Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held on June 12, 2026.
Rhea-AI Filing Summary
LENZ Therapeutics, Inc. reported the results of its 2026 annual stockholder meeting held on June 12, 2026. Of the 31,354,394 common shares outstanding as of April 14, 2026, 24,442,068 shares were represented in person or by proxy.
Stockholders elected Class II directors Evert Schimmelpennink, Jeff George, and Shelley Thunen to serve until the 2029 annual meeting, with each receiving more votes for than withheld. Stockholders also ratified the appointment of Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Shares outstanding: 31,354,394 shares
Shares represented: 24,442,068 shares
Votes for Evert Schimmelpennink: 20,216,637 votes
+5 more
8 metrics
Shares outstanding
31,354,394 shares
Common stock outstanding as of record date April 14, 2026
Shares represented
24,442,068 shares
Shares present or by proxy at 2026 annual meeting
Votes for Evert Schimmelpennink
20,216,637 votes
Election as Class II director
Votes for Jeff George
13,462,359 votes
Election as Class II director
Votes for Shelley Thunen
20,215,686 votes
Election as Class II director
Auditor ratification votes for
24,310,915 votes
Ratification of Ernst & Young LLP for FY ending Dec 31, 2026
Auditor votes against
55,181 votes
Ratification of Ernst & Young LLP
Auditor abstentions
75,972 votes
Ratification of Ernst & Young LLP
Key Terms
broker non-votes, independent registered public accounting firm, Class II directors, emerging growth company, +1 more
5 terms
broker non-votes financial
"Nominee | Votes For | Votes Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
independent registered public accounting firm financial
"The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm"
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
Class II directors financial
"The following nominees were elected to serve as Class II directors to hold office until the Company's 2029 annual meeting"
emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
broker non-votes financial
"Votes For | Votes Withheld | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did LENZ (LENZ) stockholders vote on at the 2026 annual meeting?
Stockholders voted on electing three Class II directors and ratifying Ernst & Young LLP as independent registered public accounting firm for 2026. All director nominees were elected, and the auditor ratification proposal received strong support based on votes for versus against.
Were LENZ (LENZ) Class II director nominees elected in 2026?
Yes, Class II director nominees Evert Schimmelpennink, Jeff George, and Shelley Thunen were elected. Each received more votes for than withheld, so they will serve until the 2029 annual meeting or until a successor is duly elected and qualified under the company’s governance terms.
How did stockholders vote on the LENZ (LENZ) auditor ratification for 2026?
Stockholders ratified Ernst & Young LLP as LENZ’s independent registered public accounting firm for the year ending December 31, 2026, with 24,310,915 votes for, 55,181 against, and 75,972 abstentions. There were no broker non-votes reported on this proposal.
Who signed LENZ (LENZ) 8-K reporting the 2026 annual meeting results?
The report was signed on behalf of LENZ Therapeutics, Inc. by Daniel Chevallard, the company’s Chief Financial Officer and principal financial and accounting officer. His signature confirms the company’s submission of the official voting results from the annual stockholder meeting.
AI-generated analysis. How Rhea-AI works. Not financial advice.
